We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

167 hedge funds and large institutions have $1.41B invested in Coherus Oncology in 2019 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 56 increasing their positions, 43 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

217% more call options, than puts

Call options by funds: $15.8M | Put options by funds: $4.99M

115% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 20

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

30% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 43

14% more funds holding

Funds holding: 146 → 167 (+21)

3.11% more ownership

Funds ownership: 96.32% → 99.43% (+3.1%)

5% less capital invested

Capital invested by funds: $1.47B → $1.41B (-$67.9M)

Holders
167
Holders Change
+21
Holders Change %
+14.38%
% of All Funds
3.66%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
43
Increased
56
Reduced
43
Closed
20
Calls
$15.8M
Puts
$4.99M
Net Calls
+$10.8M
Net Calls Change
+$3.31M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$26.7M
2
RHJA
Rice Hall James & Associates
California
+$14.1M
3
N
Nuveen
North Carolina
+$13.3M
4
Ameriprise
Ameriprise
Minnesota
+$9.96M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$9.81M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$15.3M
2
JP Morgan Chase
JP Morgan Chase
New York
-$11.8M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$9.99M
4
HP
Hound Partners
New York
-$9.47M
5
DCM
Driehaus Capital Management
Illinois
-$9.38M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
26
Ameriprise
Minnesota
$13.9M +$9.96M +498,282 +264%
Citadel Advisors
27
Citadel Advisors
Florida
$13.7M +$3.44M +172,187 +34%
SCM
28
Sio Capital Management
New York
$12.3M +$8.4M +420,419 +228%
AllianceBernstein
29
AllianceBernstein
Tennessee
$11.2M +$9.26M +463,479 +511%
Adage Capital Partners
30
Adage Capital Partners
Massachusetts
$10.1M -$9.99M -500,000 -50%
Fidelity International
31
Fidelity International
Bermuda
$9.53M – – –
Macquarie Group
32
Macquarie Group
Australia
$8.71M – – –
Wells Fargo
33
Wells Fargo
California
$7.97M +$2.56M +128,278 +48%
CS
34
Credit Suisse
Switzerland
$7.8M +$4.93M +246,898 +179%
Charles Schwab
35
Charles Schwab
California
$7.7M +$598K +29,952 +9%
D.E. Shaw & Co
36
D.E. Shaw & Co
New York
$7.66M +$2.48M +124,142 +49%
Federated Hermes
37
Federated Hermes
Pennsylvania
$6.68M -$4.54M -227,259 -41%
RPAM
38
Rhenman & Partners Asset Management
Sweden
$5.88M -$2M -100,000 -26%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$5.53M -$855K -42,815 -14%
Two Sigma Advisers
40
Two Sigma Advisers
New York
$5.25M +$1.36M +68,100 +36%
PCM
41
Peregrine Capital Management
Minnesota
$4.8M +$4.74M +237,091 New
Mirae Asset Global Investments
42
Mirae Asset Global Investments
South Korea
$4.54M -$1.55M -77,363 -26%
BG
43
Bellevue Group
Switzerland
$4.08M +$695K +34,800 +21%
Deutsche Bank
44
Deutsche Bank
Germany
$4.03M -$74.6K -3,732 -2%
TCM
45
Tekla Capital Management
Massachusetts
$3.95M -$1.92M -96,273 -33%
ACM
46
Atika Capital Management
New York
$3.76M -$490K -24,500 -12%
Calamos Advisors
47
Calamos Advisors
Illinois
$3.75M +$2.82M +141,364 +322%
CS
48
Candriam SCA
Luxembourg
$3.48M +$2.14M +106,919 +164%
First Trust Advisors
49
First Trust Advisors
Illinois
$3.44M +$2.8M +140,107 +473%
PIM
50
Platinum Investment Management
Australia
$3.41M – – –
1
2
3 4 5

CHRS Hedge Fund Activity: Q3 2019 in Review

167 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q3 2019, worth a combined $1.41B — down 4.6% from $1.47B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new CHRS positions and 20 closed out — a net gain of 23 holders — while 56 added to existing stakes and 43 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $26.7M. The largest seller was PFM Health Sciences, cutting an estimated $15.3M.

  • 167 institutional investors held Coherus Oncology (CHRS) as of Q3 2019, up from 146 in Q2 2019.
  • Funds reported $1.41B of Coherus Oncology stock for Q3 2019, down 4.6% quarter-over-quarter.
  • 43 funds opened new Coherus Oncology positions in Q3 2019 and 20 closed out, a net change of +23 holders.
  • The largest Coherus Oncology buyer in Q3 2019 was Rubric Capital Management (New York), an estimated $26.7M added.
  • The largest Coherus Oncology seller in Q3 2019 was PFM Health Sciences, an estimated $15.3M sold.

Based on aggregated 13F filings for Q3 2019.